B. Riley analyst issues BUY recommendation for STIM on September 11, 2026 08:47AM ET. STIM was trading at $3.01 at issue of the analyst recommendation.The overall analyst consensus : BUY.Current analyst recommendations are : 6 - Buy, 1 - Hold recommendations .Historical Analyst RecommendationsLatest 10 recommendationsReport DateAnalyst CompanyActionPrevious GradeNew GradePrice when posted 2026-09-11 B. Riley...
Morgan Stanley analyst issues UNDERWEIGHT recommendation for DC on September 11, 2026 06:19AM ET. The previous...
Key Points - Robbins LLP, Kaplan Fox & Kilsheimer LLP, Rosen Law Firm, Bernstein Liebhard LLP,...
Key Points - Rosen Law Firm reminds investors of the September 28, 2026 lead plaintiff deadline...
Vaxart, Inc. (VXRT)'s technical profile remains under pressure, according to KlickAnalytics' Technical Composite Ranking, with the...
from Wedbush issued a price target of $5.00 for TLS on 2026-09-10 20:11:11.The adjusted price target was set to $5.00.At the time of the announcement, TLS was trading at $4.68.The...
from Telsey Advisory issued a price target of $23.00 for JILL on 2026-09-10 14:31:25.The adjusted price target was set to $23.00.At the time of the announcement, JILL was trading at...
Kristen Kluska from Cantor Fitzgerald issued a price target of $11.00 for AQST on 2026-09-10 13:31:00.The adjusted price target was set to $11.00.At the time of the announcement, AQST was...
from Roth Capital issued a price target of $17.00 for LAKE on 2026-09-10 11:56:11.The adjusted price target was set to $17.00.At the time of the announcement, LAKE was trading at...
from Roth Capital issued a price target of $4.50 for EOSE on 2026-09-10 11:53:37.The adjusted price target was set to $4.50.At the time of the announcement, EOSE was trading at...
In a landscape marked by rapid technological advancements, the company saw a revenue increase of $1.4 million for the three months ending September 30, 2024, fueled by new licenses and...
In a landscape of fluctuating revenues, the company celebrated a 25% revenue increase in Q3 2024, yet faced a 14% decline over nine months due to production challenges. Operating expenses...
In a landscape marked by financial challenges, the company faced fluctuating revenues, with a notable 25% increase in Q3 2024 overshadowed by a 14% decline over nine months. Operating losses...
In a tale of growth and ambition, the company witnessed its revenue soar from $6.0 million to $13.9 million, fueled by partnerships with Acadia Pharmaceuticals. However, operating expenses, particularly in...
In a transformative period, the company experienced a remarkable surge in revenue, driven by newly acquired oil and gas assets. Operating expenses showed notable trends, with a decrease in occupancy...
